Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 56.52 percent increase over losses of $(0.23) per share from the same period last year.
Marriott’s Growth Strategy: Morgan Stanley Foresees Upside Amid Recent Market Jitters
Morgan Stanley analyst Stephen W Grambling has reiterated an Overweight rating on the shares of Marriott International Inc (NASDAQ: MAR)